Therapy/Opportunity Infections

rhG-CSF May Reduce Infection in Neutropenic AIDS Patients

Published in AIDS Weekly, July 3rd, 1995

Therapeutic use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) at appropriate schedules in neutropenic AIDS patients could decrease the risk of infection or reduce the severity of occurring infections, according to a report from Italy.

Emerging experimental evidence points to a major role for CD4 and CD8 cells in defense against Cryptococcus neoformans in the lung; natural effectors such as natural killer cells, macrophages, and polymorphonuclear leukocytes (PMNL) are also involved in controlling infection when the fungus escapes from the lung and enters the circulation. A role as effector cells has been described for human PMNL against...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1995-07-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry